VTYX - NASDAQ
Ventyx Biosciences, Inc.
$14.00
+0.0000%Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
At a Glance
Live Snapshotvtyx
Total Stockholders' Equity
Last Annual Value
254.04M
3-Year CAGR
-3%
5-Year CAGR
129%
10-Year CAGR
51%
Ventyx Biosciences, Inc. Competitors Analysis of Total Stockholders' Equity
| Company | Total Stockholders' Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Ventyx Biosciences, Inc. NASDAQ:VTYX | 254.04M | 1.4% | -1.9% | N/A | |
 KalVista Pharmaceuticals, Inc. NASDAQ:KALV | -2.71M | N/A | N/A | N/A | |
 Rigel Pharmaceuticals, Inc. NASDAQ:RIGL | 391.48M | N/A | 66.7% | 21.7% | |
 Prothena Corporation plc NASDAQ:PRTA | 280.47M | -20.6% | -9.7% | -2.6% | |
 Gossamer Bio, Inc. NASDAQ:GOSS | -122.76M | N/A | N/A | N/A | |
 REGENXBIO Inc. NASDAQ:RGNX | 102.73M | -30.9% | -33.1% | -4.4% | |
 Absci Corporation NASDAQ:ABSI | 189.45M | 2.5% | -12.3% | N/A | |
 Corvus Pharmaceuticals, Inc. NASDAQ:CRVS | 61.20M | 16.5% | -8.8% | -7.5% | |
 Olema Pharmaceuticals, Inc. NASDAQ:OLMA | 478.56M | 23.5% | 11.0% | N/A | |
 Verastem, Inc. NASDAQ:VSTM | 57.20M | -0.1% | -8.2% | -2.3% |
Ventyx Biosciences, Inc. Fair Value Envelope
Related Guides
Continue your VTYX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.